If your company is developing ibogaine or ibogaine analogs for clinical use, there’s a rare public-private opportunity in Texas you should be leveraging.

The Texas Legislature has allocated $50 million to support FDA-regulated ibogaine R&D, with a focus on partnerships involving Texas-based CDMOs and research organizations. The funding structure offers 1:1 matched support for qualified programs, but access depends on your ability to execute within the state.

At Benuvia, we are a GMP-certified, DEA Schedule I licensed CDMO located in Round Rock, Texas, with active quotas for ibogaine and four additional psychedelic compounds. We recently secured a federal NIH contract to manufacture psilocybin, reinforcing our capabilities in highly regulated Schedule I development.

Based on publicly available information, Benuvia is uniquely positioned in Texas as the primary GMP CDMO with DEA Schedule I authorization for psychedelics, a critical requirement for developers looking to align with the state’s ibogaine funding initiative.

𝗪𝗲’𝗿𝗲 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗲𝗿𝘀 𝘁𝗼:

• Enable GMP ibogaine manufacturing (API and drug product)
• Provide CMC and regulatory support toward IND or clinical trials
• Align projects with Texas’s public-private co-investment structure

If you’re evaluating options to accelerate ibogaine development, with both funding and execution in mind, we’d welcome a conversation.
Connect with us directly to explore a partnership with Benuvia.